This is the first study to identify that EVO exerts anti-CRC effects by inhibiting the Wnt/β-catenin/c-MYC pathway to specifically target ASS1, the rate-limiting enzyme in arginine synthesis, thereby inhibiting intracellular arginine metabolism. Here, MYC is linked to colorectal carcinoma.